Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?

The aim of the study was to assess the occurrence and nature of immune-related endocrine adverse events (irAEs) among patients with non-small-cell lung cancer (NSCLC) treated with nivolumab. Methods: The study group included 35 patients (15 women, 20 men, 65.8 ± 7.1 years) with NSCLC in stage IIIB (...

Descripción completa

Detalles Bibliográficos
Autores principales: Chmielewska, Izabela, Dudzińska, Marta, Szczyrek, Michał, Świrska, Joanna, Wojas-Krawczyk, Kamila, Zwolak, Agnieszka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480788/
https://www.ncbi.nlm.nih.gov/pubmed/34587185
http://dx.doi.org/10.1371/journal.pone.0257484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480788/
https://www.ncbi.nlm.nih.gov/pubmed/34587185
http://dx.doi.org/10.1371/journal.pone.0257484

Ejemplares similares